Advances of toripalimab for the treatment of melanoma / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 857-860, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-791222
ABSTRACT
On December 27, 2018, the first domestic anti-PD-1 antibody, toripalimab, was approved by the State Food and Drug Ad-ministration for the treatment of advanced melanoma after the failure of standard treatment. This represented a major breakthrough in the field of biopharmaceuticals in China and laid the foundations for pharmaceutical research and development in the field of tu-mor immunotherapy. In this article, we summarize the clinical research of the treatment of melanoma, the application of toripalimab in this field, and the global development of other anti-PD-1 antibodies, to provide guidance for the research and treatment of melano-ma in China.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Guía de Práctica Clínica
Idioma:
Chino
Revista:
Chinese Journal of Clinical Oncology
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS